Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 21:12:47 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Magle Chemoswed Q3 2023 - DSM business advancements

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Magle Chemoswed Q3 2023 - DSM business advancements

2023-10-26 09:10:00

Redeye leaves a comment on the Q3 report published by Magle yesterday. Overall, the report was in line with our expectations. While net sales came in slightly below our expectations due to a slower quarter for the contract manufacturing business, we are encouraged by the continuously growing sales from the DSM segment. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/